- The FDA has approved the expanded use of Roche Holding AG’s (OTC:RHHBY) Xofluza (baloxavir marboxil).
- The medicine has been approved to treat acute uncomplicated influenza in otherwise healthy children aged 5-12 years who have shown symptoms for no more than 48 hours.
- This marks the first single-dose oral influenza medicine approved in the US for children in this age group.
- The FDA also approved Xofluza to prevent influenza in children aged five years to less than 12 years following contact with an infected person.
- Roche said Xofluza is already FDA-approved to treat influenza in people aged 12 and above.
- Price Action: RHHBY shares are up 1.71% at $41.74 during the market session on the last check Friday.
What’s Going On With ZyVersa Stock?
ZyVersa Therapeutics shares are trading higher Monday after the company announced the publication of a scientific paper in a peer-reviewed journal that reinforces the rationale for inhibiting ASC with IC 100 to potentially attenuate cardiac comorbidities in patients with Alzheimer's Disease.
